Á lódáil...
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...
Na minha lista:
| Foilsithe in: | J Hematol Oncol |
|---|---|
| Main Authors: | , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
BioMed Central
2016
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4782349/ https://ncbi.nlm.nih.gov/pubmed/26951079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0251-8 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|